SAM
NVAX icon

Silphium Asset Management’s Novavax NVAX Stock Holding History

Silphium Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,453
Closed -$205K – 84
2018
Q3 		$205K Buy
+5,453
New +$154K 0.06% 115
2018
Q2 		– Sell
-2,941
Closed -$124K – 132
2018
Q1 		$124K Buy
+2,941
New +$118K 0.07% 64

Other funds holding NVAX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Silphium Asset Management's NVAX Position: Q4 2018 in Review

Silphium Asset Management sold out of Novavax (NVAX) in Q4 2018, closing a stake of 5,453 shares — an estimated $205K sold.

Silphium Asset Management first reported a position in NVAX in Q1 2018 and held it in 2 quarters. The position peaked at $205K in Q3 2018. 167 funds tracked by Wall St. Rank hold NVAX as of Q4 2018.

  • Silphium Asset Management reported no remaining Novavax position as of Q4 2018 after selling out during the quarter.
  • Silphium Asset Management sold 5,453 Novavax shares in Q4 2018, an estimated $205K.
  • Silphium Asset Management first reported a position in Novavax in Q1 2018 and held it in 2 quarters.
  • Silphium Asset Management's Novavax position peaked at $205K in Q3 2018.
  • 167 funds tracked by Wall St. Rank held Novavax as of Q4 2018.

Based on Silphium Asset Management's 13F filing for Q4 2018, filed 30 Jan 2025.